• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Nektar Therapeutics

+ Add to Watchlist


14.6200 USD 0.0300 0.21%

As of 20:10:00 ET on 01/23/2015.

Snapshot for Nektar Therapeutics (NKTR)

Open: 14.5500 Day's Range: 14.4000 - 14.7500 Volume: 618,148
Previous Close: 14.5900 52wk Range: 10.1000 - 17.5300 1-Yr Rtn: +13.16%

Stock Chart for NKTR

No chart data available.
  • NKTR:US 14.6200
  • 1D
  • 1M
  • 1Y
Interactive NKTR Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NKTR

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.5100
Est. EPS (USD) (12/2014) -0.4390
Est. PEG Ratio -
Market Cap (M USD) 1,877.81
Shares Outstanding (M) 128.44
30 Day Average Volume 885,769
Price/Book (mrq) 39.7091
Price/Sale (ttm) 8.6281
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/26/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NKTR

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for NKTR

Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company's product pipeline is comprised of early to late stage drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.

Howard W RobinPresident/CEOJohn L NicholsonSenior VP/CFO
Stephen K DobersteinSenior VP/Chief Scientific OfcrGil M LabrucherieSenior VP/Secy/Gen Counsel
More Company Profile & Key Executives for NKTR

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil